{"title":"GLP-1类似物在肥胖症临床治疗中的应用","authors":"Rachel Agius , Claudia Coelho , Barbara McGowan","doi":"10.1016/j.coemr.2022.100360","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Obesity is a chronic disease requiring chronic management. Anti-obesity medication for the treatment<span> of obesity includes the glucagon-like peptide-1 (GLP-1) agonists liraglutide and </span></span>semaglutide. This review will discuss the results of weight loss </span>clinical trials<span> for these agents, in addition to anorectic gut hormone<span> analogue combinations and co-agonist drugs targeting gut hormone receptors, as well as the implications for the clinical management of obesity.</span></span></p></div>","PeriodicalId":52218,"journal":{"name":"Current Opinion in Endocrine and Metabolic Research","volume":"25 ","pages":"Article 100360"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"GLP-1 analogues in clinical management of obesity\",\"authors\":\"Rachel Agius , Claudia Coelho , Barbara McGowan\",\"doi\":\"10.1016/j.coemr.2022.100360\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>Obesity is a chronic disease requiring chronic management. Anti-obesity medication for the treatment<span> of obesity includes the glucagon-like peptide-1 (GLP-1) agonists liraglutide and </span></span>semaglutide. This review will discuss the results of weight loss </span>clinical trials<span> for these agents, in addition to anorectic gut hormone<span> analogue combinations and co-agonist drugs targeting gut hormone receptors, as well as the implications for the clinical management of obesity.</span></span></p></div>\",\"PeriodicalId\":52218,\"journal\":{\"name\":\"Current Opinion in Endocrine and Metabolic Research\",\"volume\":\"25 \",\"pages\":\"Article 100360\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Endocrine and Metabolic Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S245196502200045X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Endocrine and Metabolic Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S245196502200045X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Obesity is a chronic disease requiring chronic management. Anti-obesity medication for the treatment of obesity includes the glucagon-like peptide-1 (GLP-1) agonists liraglutide and semaglutide. This review will discuss the results of weight loss clinical trials for these agents, in addition to anorectic gut hormone analogue combinations and co-agonist drugs targeting gut hormone receptors, as well as the implications for the clinical management of obesity.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
